Yoko Ueno

MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs <i>In vitro</i> and <i>In vivo</i>

Hiroshi Hirai, Hiroshi Sootome, Yoko Nakatsuru et al. · Molecular Cancer Therapeutics · 2010 · 938 citations · Full text

Medicine, Oncology, Pharmacology +17

Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia

Masamichi Mori, Naoki Kaneko, Yoko Ueno et al. · Investigational New Drugs · 2017 · 254 citations · Full text

Medicine, Oncology, Pharmacology +16

Effect of Fms-like tyrosine kinase 3 (FLT3) ligand (FL) on antitumor activity of gilteritinib, a FLT3 inhibitor, in mice xenografted with FL-overexpressing cells

Tatsuya Kawase, Taisuke Nakazawa, Tomohiro Eguchi et al. · Oncotarget · 2019 · 83 citations · Full text

Medicine, Oncology, Pharmacology +13

Heregulin‐induced activation of ErbB3 by EGFR tyrosine kinase activity promotes tumor growth and metastasis in melanoma cells

Yoko Ueno, Hiroaki Sakurai, Satoshi Tsunoda et al. · International Journal of Cancer · 2008 · 73 citations

Medicine, Cancer Biology, Oncology +17

Activation of MEK/ERK and PI3K/Akt pathways by fibronectin requires integrin αv‐mediated ADAM activity in hepatocellular carcinoma: A novel functional target for gefitinib

Mitsuhiro Matsuo, Hiroaki Sakurai, Yoko Ueno et al. · Cancer Science · 2006 · 67 citations · Full text

Medicine, Oncology, Pharmacology +17